Cargando…

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective

Therapy resistance and tumor recurrence are often linked to a small refractory and highly tumorigenic subpopulation of neoplastic cells, known as cancer stem cells (CSCs). A putative marker of CSCs is CD133 (prominin-1). We have previously described a CD133-targeted oncolytic measles virus (MV-CD133...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleinlützum, Dina, Hanauer, Julia D. S., Muik, Alexander, Hanschmann, Kay-Martin, Kays, Sarah-Katharina, Ayala-Breton, Camilo, Peng, Kah-Whye, Mühlebach, Michael D., Abel, Tobias, Buchholz, Christian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483446/ https://www.ncbi.nlm.nih.gov/pubmed/28695108 http://dx.doi.org/10.3389/fonc.2017.00127

Ejemplares similares

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
por: Muik, Alexander, et al.
Publicado: (2012)

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma
por: Hanauer, Julia D.S., et al.
Publicado: (2018)

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors
por: Hanauer, Jan RH, et al.
Publicado: (2016)

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
por: Simovic, Boris, et al.
Publicado: (2015)

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Hastie, Eric, et al.
Publicado: (2016)

Hydrodynamic characterization of a vesicular stomatitis virus-based oncolytic virus using analytical ultracentrifugation
por: Wawra, Simon, et al.
Publicado: (2023)

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer
por: Heiber, Joshua F., et al.
Publicado: (2011)

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
por: Bourgeois-Daigneault, Marie-Claude, et al.
Publicado: (2016)

Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells
por: Kim, Teddy E., et al.
Publicado: (2021)

Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells
por: Garijo, Raquel, et al.
Publicado: (2014)

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells
por: Corredor, Juan C, et al.
Publicado: (2016)

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
por: Goad, Dakota W., et al.
Publicado: (2023)

Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity
por: Ayala Breton, Camilo, et al.
Publicado: (2015)

The synthetic futures of vesicular stomatitis virus
por: Overend, Christopher, et al.
Publicado: (2012)

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia
por: Betancourt, Dillon, et al.
Publicado: (2015)

Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells
por: Seegers, Sara L., et al.
Publicado: (2020)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
por: Naik, Shruthi, et al.
Publicado: (2012)

Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models
por: Le Boeuf, Fabrice, et al.
Publicado: (2017)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions
por: Holbrook, Molly C., et al.
Publicado: (2021)

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Goad, Dakota W., et al.
Publicado: (2021)

Designing and building oncolytic viruses
por: Maroun, Justin, et al.
Publicado: (2017)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
por: Packiriswamy, Nandakumar, et al.
Publicado: (2020)

EFFECT OF FORMALIN ON THE VIRUS OF VESICULAR STOMATITIS OF HORSES
por: Olitsky, Peter K., et al.
Publicado: (1928)

Transmembrane biogenesis of the vesicular stomatitis virus glycoprotein
Publicado: (1979)

Oncolytic Viruses: Priming Time for Cancer Immunotherapy
por: Russell, Luke, et al.
Publicado: (2019)

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines
por: Bridle, Byram W, et al.
Publicado: (2013)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Publicado: (2021)

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
por: Rangsitratkul, Coby, et al.
Publicado: (2022)

RIG‐I‐mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus
por: Zhang, Pengfei, et al.
Publicado: (2022)

Gamma interferon expression and major histocompatibility complex induction during measles and vesicular stomatitis virus infections of the brain
por: Gogate, Nitin, et al.
Publicado: (1991)

Measles to the Rescue: A Review of Oncolytic Measles Virus
por: Aref, Sarah, et al.
Publicado: (2016)

Measles virus: Background and oncolytic virotherapy
por: Bhattacharjee, Sankhajit, et al.
Publicado: (2018)

Vaccine platform recombinant measles virus
por: Mühlebach, Michael D.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_697ds2e3sgstb1tqoeitkja1o5